Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTXQ BioRestorative Therapies	$1.52 +1.3%	$1.61	$0.00 ▼ $0.06	$2.49B	102.36	62.17 million shs	25,791 shs
GH Guardant Health	$58.88 -2.5%	$49.22	$20.14 ▼ $60.68	$7.34B	1.43	3.21 million shs	3.20 million shs
OPCH Option Care Health	$28.32 -0.3%	$30.29	$21.39 ▼ $35.53	$4.60B	0.79	1.60 million shs	1.18 million shs
RDNT RadNet	$67.45 -1.9%	$57.37	$45.00 ▼ $93.65	$5.19B	1.43	996,862 shs	1.39 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTXQ BioRestorative Therapies	0.00%	+4.83%	-4.40%	-5.59%	-4.40%
GH Guardant Health	0.00%	+8.57%	+26.73%	+46.32%	+110.66%
OPCH Option Care Health	0.00%	+0.43%	-3.93%	-14.42%	-9.72%
RDNT RadNet	0.00%	+26.41%	+17.32%	+11.19%	+4.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRTXQ BioRestorative Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	3.18 of 5 stars	1.5	2.0	0.0	4.4	2.8	2.5	0.6
OPCH Option Care Health	4.6572 of 5 stars	3.4	3.0	0.0	4.3	3.7	1.7	1.9
RDNT RadNet	3.3141 of 5 stars	1.7	2.0	0.0	4.6	3.8	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRTXQ BioRestorative Therapies	0.00	N/A	N/A	N/A
GH Guardant Health	3.06	Buy	$57.50	-2.34% Downside
OPCH Option Care Health	2.89	Moderate Buy	$35.75	26.24% Upside
RDNT RadNet	3.43	Buy	$71.60	6.15% Upside

Current Analyst Ratings Breakdown

Latest BRTXQ, GH, RDNT, and OPCH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	RDNT RadNet	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$66.00 ➝ $75.00
8/11/2025	RDNT RadNet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
7/31/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$36.00 ➝ $38.00
7/31/2025	OPCH Option Care Health	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00
7/31/2025	GH Guardant Health	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$59.00 ➝ $61.00
7/14/2025	GH Guardant Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	RDNT RadNet	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$74.00
7/10/2025	OPCH Option Care Health	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$38.00
6/18/2025	OPCH Option Care Health	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$36.00
6/13/2025	GH Guardant Health	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $65.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRTXQ BioRestorative Therapies	$110K	22,656.65	N/A	N/A	($0.68) per share	-2.24
GH Guardant Health	$739.02M	9.94	N/A	N/A	($1.13) per share	-52.11
OPCH Option Care Health	$5.00B	0.92	$1.64 per share	17.22	$8.25 per share	3.43
RDNT RadNet	$1.83B	2.84	$3.48 per share	19.36	$15.31 per share	4.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRTXQ BioRestorative Therapies	-$12.52M	-$1.07	N/A	∞	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	11/5/2025 (Estimated)
OPCH Option Care Health	$211.82M	$1.25	22.66	22.48	1.79	3.93%	17.53%	7.17%	10/29/2025 (Estimated)
RDNT RadNet	$2.79M	-$0.20	N/A	127.26	N/A	-0.78%	2.41%	0.82%	N/A

Latest BRTXQ, GH, RDNT, and OPCH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2025	Q2 2025	RDNT RadNet	$0.17	$0.31	+$0.14	$0.43	$488.06 million	$498.23 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million
7/30/2025	Q2 2025	OPCH Option Care Health	$0.40	$0.41	+$0.01	$0.31	$1.35 billion	$1.42 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRTXQ BioRestorative Therapies	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
OPCH Option Care Health	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRTXQ BioRestorative Therapies	N/A	N/A	N/A
GH Guardant Health	N/A	3.71	3.35
OPCH Option Care Health	0.81	1.52	1.00
RDNT RadNet	0.91	2.00	2.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRTXQ BioRestorative Therapies	N/A
GH Guardant Health	92.60%
OPCH Option Care Health	98.05%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
BRTXQ BioRestorative Therapies	12.20%
GH Guardant Health	6.10%
OPCH Option Care Health	0.64%
RDNT RadNet	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRTXQ BioRestorative Therapies	7	1.64 billion	N/A	Not Optionable
GH Guardant Health	2,021	124.71 million	117.10 million	Not Optionable
OPCH Option Care Health	8,088	162.29 million	161.26 million	Optionable
RDNT RadNet	11,021	76.92 million	72.61 million	Optionable

BRTXQ, GH, RDNT, and OPCH Headlines

Recent News About These Companies

Invesco Ltd. Sells 210,244 Shares of RadNet, Inc. (NASDAQ:RDNT)

1 hour ago | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Decreases Holdings in RadNet, Inc. (NASDAQ:RDNT)

1 hour ago | marketbeat.com

Vanguard Group Inc. Cuts Stake in RadNet, Inc. (NASDAQ:RDNT)

1 hour ago | marketbeat.com

Insider Selling: RadNet, Inc. (NASDAQ:RDNT) EVP Sells 17,000 Shares of Stock

August 17 at 8:59 AM | marketbeat.com

Neuberger Berman Group LLC Purchases 58,698 Shares of RadNet, Inc. (NASDAQ:RDNT)

August 17 at 5:31 AM | marketbeat.com

RadNet (NASDAQ:RDNT) Stock Rating Upgraded by Wall Street Zen

August 17 at 2:16 AM | marketbeat.com

B. Riley Brokers Increase Earnings Estimates for RadNet

August 16 at 9:41 AM | marketbeat.com

David Jeffrey Katz Sells 17,000 Shares of RadNet, Inc. (NASDAQ:RDNT) Stock

August 16 at 8:04 AM | insidertrades.com

Oak Ridge Investments LLC Acquires Shares of 35,464 RadNet, Inc. (NASDAQ:RDNT)

August 16 at 8:03 AM | marketbeat.com

Raymond James Financial Reiterates "Strong-Buy" Rating for RadNet (NASDAQ:RDNT)

August 15 at 9:07 AM | marketbeat.com

Public Sector Pension Investment Board Purchases 44,361 Shares of RadNet, Inc. (NASDAQ:RDNT)

August 15 at 5:18 AM | marketbeat.com

Citigroup Inc. Raises Position in RadNet, Inc. (NASDAQ:RDNT)

August 15 at 4:12 AM | marketbeat.com

Raymond James Financial Reaffirms "Strong-Buy" Rating for RadNet (NASDAQ:RDNT)

August 15 at 3:55 AM | americanbankingnews.com

Deutsche Bank AG Lowers Position in RadNet, Inc. (NASDAQ:RDNT)

August 15 at 3:42 AM | marketbeat.com

B. Riley Weighs in on RadNet's Q3 Earnings (NASDAQ:RDNT)

August 15 at 2:21 AM | americanbankingnews.com

Research Analysts Offer Predictions for RadNet Q3 Earnings

August 14, 2025 | marketbeat.com

AGF Management Ltd. Trims Holdings in RadNet, Inc. (NASDAQ:RDNT)

August 14, 2025 | marketbeat.com

RadNet, Inc. (NASDAQ:RDNT) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

RadNet (NASDAQ:RDNT) Shares Gap Up - Here's Why

August 12, 2025 | marketbeat.com

RadNet (NASDAQ:RDNT) Announces Earnings Results, Beats Expectations By $0.14 EPS

August 12, 2025 | marketbeat.com

Natixis Advisors LLC Trims Stock Holdings in RadNet, Inc. (NASDAQ:RDNT)

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BRTXQ, GH, RDNT, and OPCH Company Descriptions

BioRestorative Therapies OTCMKTS:BRTXQ

$1.52 +0.02 (+1.33%)

As of 08/15/2025

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.

Guardant Health NASDAQ:GH

$58.88 -1.48 (-2.45%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$58.37 -0.51 (-0.87%)

As of 04:00 AM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Option Care Health NASDAQ:OPCH

$28.32 -0.09 (-0.32%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$28.60 +0.28 (+0.99%)

As of 04:08 AM Eastern

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.

RadNet NASDAQ:RDNT

$67.45 -1.30 (-1.89%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$67.51 +0.06 (+0.09%)

As of 04:04 AM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time